1H Magnetic Resonance Spectroscopy Assessment of the Effects of Rivastigmine on Patients with moderate Alzheimer Disease.

Publicado: 2005-09-17

   Arturo Alvarado

Universidad Central de Veneazuela Facultad de Medicina Instituto de Medicina Experimental Unidad de detección de medicamentos (UNIDEME) Cátedra de Farmacología y Toxicología

   Yelena Figueroa

Hospital Psiquiatrico "El Peñon"

   Alberto Mendoza

Hospital Psiquiatrico "El Peñon"

   Hodalitz Ortiz

Instituto de Resonancia Magnetica "La Florida-San Román" Caracas, Venezuela

   Valentina Itriago

Instituto de Resonancia Magnetica "La Florida-San Román" Caracas, Venezuela

   Mariangela Alvarado

Universidad Central de Venezuela Facultad de Medicina "Escuela Luis Razetti"

Resumen

Alzheimer's disease (AD) is a progressive neurological condition that results in the irreversible loss of neurons, particularly in the cortex and hippocampus. The clinical hallmarks are progressive impairment in memory, judgment, decision making, orientation to physical surroundings, and language. In 1906, Alois Alzheimer defined the clinicopathological syndrome that bears his name at a meeting in Munich. When he described the disorder in a woman in her early 50s, neither he nor his audience recognized that AD might ultimately turn out to be indistinguishable from common senile dementia (1, 2). 

Detalles del artículo

Artículos más leídos del mismo autor/a